Detalhe da pesquisa
1.
Ki-67 (30-9) scoring and differentiation of Luminal A- and Luminal B-like breast cancer subtypes.
Breast Cancer Res Treat
; 178(2): 451-458, 2019 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-31422497
2.
Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial.
Breast Cancer Res Treat
; 176(3): 557-568, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-31065870
3.
Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer : Intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be the cause of discordance.
Breast Cancer Res Treat
; 155(3): 463-9, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26820652
4.
ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer.
Breast Cancer Res Treat
; 154(3): 543-55, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26590813
5.
Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.
Breast Cancer Res Treat
; 154(2): 275-86, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26493064
6.
CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.
Breast Cancer Res Treat
; 151(2): 373-84, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25935582
7.
Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study.
Breast Cancer Res Treat
; 143(3): 485-92, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24395109
8.
HER2 heterogeneity and treatment response-associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial.
J Clin Invest
; 134(7)2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38300710
9.
The clinical relevance of micropapillary carcinoma of the breast: a case-control study.
Histopathology
; 63(2): 217-24, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23763700
10.
Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial.
Breast Cancer Res
; 14(3): R70, 2012 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-22551440
11.
The biological features and prognosis of breast cancer diagnosed during pregnancy: a case-control study.
Acta Oncol
; 51(5): 653-61, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-22171586
12.
Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab.
Cancer Discov
; 11(10): 2474-2487, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33941592
13.
Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
Lancet Oncol
; 9(1): 23-8, 2008 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-18083065
14.
Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial.
JAMA Oncol
; 4(10): 1335-1343, 2018 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29902286
15.
The Dilemma of HER2 Double-equivocal Breast Carcinomas: Genomic Profiling and Implications for Treatment.
Am J Surg Pathol
; 42(9): 1190-1200, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29975246
16.
HER2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17.
Eur J Cancer
; 43(16): 2339-44, 2007 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-17855075
17.
Immunohistochemical Performance of Estrogen and Progesterone Receptor Antibodies on the Dako Omnis Staining Platform: Evaluation in Multicenter Studies.
Appl Immunohistochem Mol Morphol
; 25(5): 313-319, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-26657878
18.
HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2.
Eur J Cancer
; 79: 129-138, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28494403
19.
Detecting cell-free circulating hTERT mRNA in the plasma may identify a subset of nonsmall cell lung cancer patients.
Virchows Arch
; 448(1): 7-15, 2006 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-16193293
20.
Assessment of HER2 amplification status in breast cancer using a new automated HER2 IQFISH pharmDx™ (Dako Omnis) assay.
Pathol Res Pract
; 212(8): 735-42, 2016 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-27461826